These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27924636)

  • 1. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.
    Raccah D
    Expert Opin Drug Saf; 2017 Feb; 16(2):227-236. PubMed ID: 27924636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.
    Cornell S
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):17-27. PubMed ID: 32910490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
    Hanefeld M; Raccah D; Monnier L
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.
    Dahiya L; Kaur R; Kumar R; Kumar M; Palta K
    Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
    Peng H; Want LL; Aroda VR
    Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2013 Nov; 14(16):2281-96. PubMed ID: 24087882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
    Russell-Jones D
    Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
    Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and tolerability of GLP-1 receptor agonists].
    Soldevila B; Puig-Domingo M
    Med Clin (Barc); 2014; 143 Suppl 2():35-40. PubMed ID: 25326842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
    Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Jespersen MJ; Knop FK; Christensen M
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel GLP-1 receptor agonists for diabetes.
    Garber AJ
    Expert Opin Investig Drugs; 2012 Jan; 21(1):45-57. PubMed ID: 22111970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].
    Ritz C; Jaafar J; Philippe J
    Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.